Liu Xiao, Cui Qianqian
Department of Breast Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, 110042, People's Republic of China.
Department of Breast Surgery, Altaira Nursing Service, Campbelltown, NSW, SA 5074, Australia.
Int J Gen Med. 2022 Dec 3;15:8451-8465. doi: 10.2147/IJGM.S388537. eCollection 2022.
Although (CDGSH iron sulfur domain 1) is upregulated in many cancer types, the potential role of in breast cancer is still unclear. The purpose of this study was to investigate its clinical significance in breast cancer.
We obtained 1109 breast cancer samples and 113 normal samples from The Cancer Genome Atlas (TCGA) and GTEx databases to demonstrate the relationship between expression and pancancer characteristics. We analysed the relationship between and breast cancer using the -test and the chi-square test to evaluate the expression level of and its clinical significance in breast cancer. The prognostic value of in breast cancer was determined by Kaplan‒Meier and Cox regression analyses. The biological pathways were screened by gene set analysis and Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and single-sample gene set enrichment analysis (ssGSEA), of which the correlation between the level of immune infiltration and the expression of in breast cancer was then analysed. Finally, we verified the conclusion by qPCR, immunohistochemistry, and CCK8.
is highly expressed in breast cancer patients. In addition, we verified a higher expression of expressed in the BRCA (breast cancer) cell line, whereas has a high diagnostic value, with an AUC of 0.718. Kaplan‒Meier survival and Cox regression analyses showed that high expression of was independently associated with adverse clinical outcomes. In turn, GO and KEGG analyses showed that most genes were related to rRNA metabolic process, rRNA processing. Moreover, PCR and immunohistochemistry showed that in breast cancer tissues was upregulated significantly, with CCK8 results showing that the proliferation of breast cancer cells decreased after knockout.
A high level of is associated with poor prognosis and immune infiltration in breast cancer.
尽管CDGSH铁硫结构域1（CDGSH iron sulfur domain 1）在多种癌症类型中上调，但其在乳腺癌中的潜在作用仍不清楚。本研究的目的是探讨其在乳腺癌中的临床意义。
我们从癌症基因组图谱（The Cancer Genome Atlas，TCGA）和基因型组织表达（Genotype-Tissue Expression，GTEx）数据库中获取了1109份乳腺癌样本和113份正常样本，以证明CDGSH铁硫结构域1表达与泛癌特征之间的关系。我们使用t检验和卡方检验分析CDGSH铁硫结构域1与乳腺癌的关系，以评估CDGSH铁硫结构域1的表达水平及其在乳腺癌中的临床意义。通过Kaplan-Meier和Cox回归分析确定CDGSH铁硫结构域1在乳腺癌中的预后价值。通过基因集分析、基因本体论（Gene Ontology，GO）、京都基因与基因组百科全书（Kyoto Encyclopedia of Genes and Genomes，KEGG）和单样本基因集富集分析（single-sample gene set enrichment analysis，ssGSEA）筛选生物学途径，然后分析乳腺癌中免疫浸润水平与CDGSH铁硫结构域1表达之间的相关性。最后，我们通过qPCR、免疫组织化学和CCK8验证了结论。
CDGSH铁硫结构域1在乳腺癌患者中高表达。此外，我们验证了在乳腺癌（BRCA）细胞系中CDGSH铁硫结构域1的较高表达，而CDGSH铁硫结构域1具有较高的诊断价值，曲线下面积（AUC）为0.718。Kaplan-Meier生存分析和Cox回归分析表明，CDGSH铁硫结构域1的高表达与不良临床结局独立相关。反过来，GO和KEGG分析表明，大多数基因与核糖体RNA代谢过程、核糖体RNA加工有关。此外，PCR和免疫组织化学表明，乳腺癌组织中的CDGSH铁硫结构域1显著上调，CCK8结果表明，敲除CDGSH铁硫结构域1后乳腺癌细胞的增殖减少。
CDGSH铁硫结构域1的高水平与乳腺癌的不良预后和免疫浸润相关。
